XML 94 R43.htm IDEA: XBRL DOCUMENT v3.19.3
Acquisitions - Narrative (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Aug. 23, 2018
Apr. 20, 2017
Sep. 30, 2018
Sep. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Dec. 31, 2018
Jul. 23, 2018
Finite-Lived Intangible Assets [Line Items]                
Contingent consideration payable         $ 344,900   $ 310,240  
Deferred consideration payable         $ 19,300   $ 18,300  
Issuance of common stock related to acquisition       $ 155,861   $ 155,861    
Useful life         7 years      
Loans               $ 10,000
Non-collaborative Arrangement Transactions | Marathon Pharmaceuticals, LLC                
Finite-Lived Intangible Assets [Line Items]                
Cash consideration   $ 75,000            
Equity Interest Issued, number of shares (in shares)   6,683,598            
Numerator for calculation of number of shares of equity interests issued to acquire entity   $ 65,000            
Trading day period   15 days            
Development milestone payments which the entity is obligated to pay   $ 50,000            
Agilis                
Finite-Lived Intangible Assets [Line Items]                
Cash consideration $ 49,221              
Equity Interest Issued, number of shares (in shares) 3,500,907              
Fair value of PTC common stock issued $ 155,860              
Estimated fair value of contingent consideration payable 290,500              
Deferred consideration payable 38,100              
Consideration Transferred 533,681              
Acquisition Related Costs           1,500    
Net loss attributable to common stockholders       (52,458)   (89,976)    
Issuance of common stock related to acquisition (in shares)             3,500,907  
Numerator for calculation of number of shares of equity interests issued to acquire entity $ 150,000              
Trading day period 10 days              
Earnings (loss) of acquire since acquisition date     $ (1,900)          
Development milestone payments which the entity is obligated to pay $ 40,000           $ 40,000  
Agilis | Non-collaborative Arrangement Transactions                
Finite-Lived Intangible Assets [Line Items]                
Development milestone payments which the entity is obligated to pay         $ 40,000      
Acquisition-related Costs | Agilis                
Finite-Lived Intangible Assets [Line Items]                
Net loss attributable to common stockholders       $ 800   $ 1,500    
Maximum | Agilis                
Finite-Lived Intangible Assets [Line Items]                
Priority review voucher amount         535,000   535,000  
Net sales amount         $ 150,000   $ 150,000  
Product sales         6.00%   6.00%  
Development milestone payments which the entity is obligated to pay         $ 60,000   $ 60,000  
Minimum | Agilis                
Finite-Lived Intangible Assets [Line Items]                
Product sales         2.00%   2.00%